Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-14: Adagrasib + BI 1701963 in KRAS G12C Solid Tumors
NCT04975256Phase 1Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adagrasib and BI 1701963 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Number of patients with treatment emergent adverse events at 20 months, Pharmacokinetics of the combination regimen at 20 months and 1 more. Started Jul 2021; status: terminated.
02
Drugs
adagrasibBI 1701963
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04975256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975256.